CA-AFFINITY
16.6.2022 12:02:09 CEST | Business Wire | Press release
Affinity , the relationship intelligence platform for dealmakers, and Dealroom.co, a global provider of data and intelligence on startups and tech ecosystems, today announced a partnership to provide the most powerful combination of predictive intelligence and relationship intelligence for dealmakers. The partnership will provide Affinity clients with additional data intelligence for over 1.7 million startups and 2.1 million organizations globally. Joint clients of both Affinity and Dealroom.co will be able to access even more insights through additional data columns.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005042/en/
“Our clients use Affinity to find, manage, and close the most important deals, and using organizational data insights helps them to target the right organizations is a critical part of their success,“ said Ray Zhou , CEO of Affinity. “Adding Dealroom.co’s predictive intelligence data to Affinity will ensure they can do that faster and with more confidence than ever before. ”
Affinity’s platform will integrate Dealroom.co’s wide range of critical data to enrich organizational records with additional firmographic data, predictive data insights, and leading market momentum indicators (such as social engagement). This will enable investors, M&A professionals, and other dealmakers to deliver the most complete understanding of deal opportunities and reduce the time they spend deciding which deals or organizations to focus on. Joint clients of both organizations will also receive access to additional Dealroom.co data columns in Affinity, including app downloads, website traffic, and founders’ history of success, further streamlining organizational intelligence gathering.
“As the intelligence layer for tech ecosystems, we help clients discover the world’s most promising companies through predictive intelligence,” said Yoram Wijngaarde , Founder and CEO at Dealroom.co. “This partnership puts this timely data into the hands of more investors around the world. We're excited to work with Affinity to provide investors with the data they need to be successful.”
Learn more about the power of Affinity and Dealroom.co’s data in the recently released joint report “Relationship Intelligence Benchmark Report: European Unicorn Edition ,” and watch the “European Unicorn Trends: How to Make Unicorn Hunting More Predictable ” webinar which brings industry experts together to discuss the trends impacting dealmakers as well as the role relationship intelligence plays in the evolving market landscape.
Across the Affinity platform, over 500,000 new introductions are made and 450,000 deals are managed per month, helping dealmakers to find, manage, and close more deals. Currently, Affinity serves over 2,000 clients worldwide, including 500 in Europe where many already use Dealroom.co data in their dealmaking process. By capturing the exhaust of relationship interactions—over 18 trillion emails and 213 million calendar invites to date—Affinity automates the creation of contact and company records and tracks activity saving over 220 hours every year in data entry work.
About Affinity
Affinity is a relationship intelligence platform that empowers dealmakers in relationship-driven industries to find, manage and close more deals. With the most automated relationship intelligence insights and technology, Affinity enables leaders to drive deals, free themselves from data drudgery and ensure their teams can take action with confidence, knowing the context and history of every relationship. The Affinity platform, including Affinity CRM, is used by over 2,000 relationship-driven organizations around the world. Founded in 2014, Affinity is headquartered in San Francisco and backed by leading investors including Menlo Ventures, Advance Venture Partners, 8VC and MassMutual Ventures.
About Dealroom.co
Dealroom.co is the foremost data provider on startups, innovation, high-growth companies,
ecosystems, and emerging tech. Founded in Amsterdam in 2013, Dealroom.co works with many of the world’s most prominent investors, entrepreneurs, and government organizations to provide transparency, analysis, and insights on venture capital activity. Dealroom.co mission is to accelerate entrepreneurship and innovation through data, insights, and predictive intelligence.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom